400 results about "Tryptamines" patented technology

The present invention provides a dry powder formulation of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. The formulations described herein may be used to treat a disease or condition, such as depression or alcohol use disorder in a subject in need thereof.

Provided herein are compounds of Formula I, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R8, R9, X, Y, Z, W, and m are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula I or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipients, and methods of using the same, e.g., in the treatment of mental health diseases and / or disorders.

Pharmaceutical compositions for the transmucosal delivery of N-N-dimethyltryptamine (DMT) acceptable salt or prodrug thereof in combination with a monoamine oxidase inhibitor to achieve desired bioavailability suitable for the treatment of neurological disorders.

A composition of a compound represented by FIGS. 1A-1E for use in treating a medical disorder. A method of changing neurotransmission, by administering a pharmaceutically effective amount of composition to a mammal of a compound represented by FIGS. 1A-1E and inducing psychoactive effects in the mammal. A method of treating a patient having adverse reactions to psychedelics or entactogens, by administering a pharmaceutically effective amount of composition to the patient of a compound represented by FIGS. 1A-1E and avoiding adverse effects present with psychedelics or entactogens.

A composition of a compound represented by FIGURES 1 A-1 E for use in treating a medical disorder. A method of changing neurotransmission, by administering a pharmaceutically effective amount of composition to a mammal of a compound represented by FIGURES 1 A-1 E and inducing psychoactive effects in the mammal. A method of treating a patient having adverse reactions to psychedelics or entactogens, by administering a pharmaceutically effective amount of composition to the patient of a compound represented by FIGURES 1 A-1 E and avoiding adverse effects present with psychedelics or entactogens.

This invention relates to pharmaceutically acceptable tryptamine analogues and salts thereof. In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament.

Crystalline hydrobromide salt of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT HBr).

The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.

The present invention provides a dry powder formulation of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. The formulations described herein may be used to treat a disease or condition, such as depression or alcohol use disorder in a subject in need thereof.

Disclosed herein are compounds, compositions, and methods for promoting neuronal growth and / or improving neuronal structure with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the loss of synaptic connectivity and / or plasticity, such as neurological diseases and disorders, with non-hallucinogenic psychoplastogens.

The present disclosure provides engineered transaminase polypeptides for the production of amines, polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to prepare compounds useful in the production of active pharmaceutical agents.

Provided are methods, prokaryotic host cells, expression vectors, and kits for the production of psilocybin derivatives produced using at least one psilocybin production gene. The methods enable production of psilocybin derivatives and related compounds including non-naturally occurring species. In certain embodiments, a prokaryotic host cell is selected from the group consisting of from the group consisting of Escherichia coli, Corynebacterium glutamicum, Vibrio natriegens, Bacillus subtilis, Bacillus megaterium, Escherichia coli Nissle 1917, Clostridium acetobutlyicum, Streptomyces coelicolor, Lactococcus lactis, Pseudomonas putida, Streptomyces clavuligerus, and Streptomyces venezuelae.

The invention belongs to the technical field of iron ion detection, and particularly relates to a rapid detection method for ferric ions in water, which comprises the following steps: a fluorescent probe preparation step: taking trihydrate of copper nitrate and tryptamine, adding into a centrifuge tube in sequence, adding ultrapure water, performing ultrasonic dissolution, transferring into a high-pressure reaction kettle, and performing hydrothermal reaction to obtain a fluorescent probe; cooling to room temperature, centrifuging the obtained yellow green solution in a centrifugal machine, and filtering the supernate through a microfiltration membrane to obtain a copper-doped carbon quantum dot CuCDs stock solution, namely the fluorescent probe; analyzing and determining Fe < 3 + >: taking the diluent of the prepared CuCDs solution, adding the diluent into a centrifugal tube containing a Fe < 3 + > standard solution, uniformly mixing, carrying out fluorescent quantitative analysis and detection, and exploring the change rule of the fluorescence intensity ratio of CuCDs; according to the rapid detection method for Fe < 3 + > provided by the invention, the synthesized CuCDs have high sensitivity, can realize on-site rapid detection of Fe < 3 + > in a water medium, and shows a wide application prospect in the field of environmental monitoring.

A method of purifying 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is provided which comprises dissolving crude 5-MeO-DMT in a solvent at a temperature above room temperature, cooling the obtained solution to a temperature below room temperature to precipitate solid 5-MeO-DMT, separating the solid 5-MeO-DMT from the remaining solution and removing solvent from the crystalline 5-MeO-DMT. In the method, the solvent comprises one or more ethers and less than 5 wt % anti-solvent.

The invention discloses a method for synchronously, efficiently and directionally preparing indirubin and tryptanthrin by using a blue grass raw material, which comprises the following steps: pretreating blue grass to obtain blue grass powder or slurry; adding water into the blue grass powder or slurry, then adding a precursor substance, and carrying out ultrasonic or microwave treatment; according to different target products, static conversion or dynamic conversion can be carried out, or static conversion or dynamic conversion is carried out after microorganisms producing cellulase and oxygenase are inoculated, and the products are subjected to post-treatment such as drying and grinding. The method is simple to operate, high in processing efficiency, flexible in product scheme, low in production cost and suitable for large-scale production. The content of the indole alkaloid in the obtained material rich in the indole alkaloid is 1%-10%; the yield of indirubin reaches 5.64 mg / g, which is 21.7 times that of the traditional process; and the tryptanthrin yield reaches 7.68 mg / g, which is 10.8 times that of the traditional process.

To provide a compound useful for the treatment of mental disorders, such as a depressive condition including unipolar and bipolar depressive conditions, for example, but not limited to, depression, depression from generalized anxiety, major depression, treatment resistant depression, and postpartum depression.SOLUTION: The present invention provides a tryptamine prodrug compound represented by the following formula.SELECTED DRAWING: Figure 1

This invention belongs to the field of pharmaceutical chemistry, and specifically relates to a compound antifungal cream containing the traditional Chinese medicine ingredient tryptamine ketone and its application. The invention comprises the following components, with the following percentage content: stearic acid 10%~16%, glyceryl monostearate 3%~7%, liquid paraffin 5%~9%, tryptamine 0.1%~0.01%, terbinafine hydrochloride 0.00625%~0.000625%, glycerin 4%, triethanolamine 2%~6%, ethylparaben 0.5%, and the balance being purified water or distilled water. This invention is highly effective, low in toxicity, and exhibits low drug resistance.

The invention relates to a method for producing tryptamine. Disclosed herein are prokaryotic and eukaryotic microorganisms, including Escherichia coli and Saccharomyces cerevisiae, genetically altered to biosynthesize tryptamine and tryptamine derivatives. Microorganisms of the present disclosure may be engineered to comprise a plasmid and a stable gene integration containing genetic information sufficient to convert anthranilic acid or indole to tryptamine. Fermentative production of substituted tryptamine in the presence of a whole-cell biocatalyst can be used to economically and efficiently produce these compounds for therapeutic use.

The disclosure relates to 2-(5-hydroxy-1H-indol-3-yl)ethan-1-aminium hydrate chloride (5-HT hydrochloride hydrate) and its crystalline form 1, and to pharmaceutical compositions containing 5-HIT hydrochloride hydrate or its crystalline form 1 and to methods of treatment using them. The disclosure further relates to crystalline form 1 of (2E)-but-2-enedioic acid bis({2-[4-(acetyloxy)-1H-indol-3-yl]ethyl}(ethyl) propylazanium) (2E)-but-2-enedioate (4-AcO-EPT fumarate fumaric acid), and to pharmaceutical compositions containing crystalline form 1 of 4-AcO-EPT fumarate fumaric acid and to methods of treatment using it. The disclosure further relates to [2-(1H-indol-3-yl)ethyl](methyl)propylavanium iodide (MPT iodide) and its crystalline form 1. and to pharmaceutical compositions containing MPT iodide or its crystalline form 1 and to methods of treatment using them. The disclosure further relates to bis(ethyl[2-(1H-indol-3-yl)ethyl]propylazanium) (2E)-but-2-enedioate (EPT fumarate) and its crystalline form 1, and to pharmaceutical compositions containing EPT fumarate or its crystalline form I and to methods of treatment using them. EPT fumarate is a novel compound and crystalline form.

The invention belongs to the technical field of organic compound preparation, and discloses a tryptanthrin compound as well as a preparation method and application thereof. The preparation method of the tryptanthrin compound disclosed by the invention comprises the step of enabling an indole-2, 3-diketone derivative, 2H-thieno [3, 2-D] [1, 3] oxazine-2, 4 (1H)-diketone, triethylamine and methylbenzene to react, so as to obtain the tryptanthrin compound. The obtained tryptanthrin compound is novel in structure, shows ulcerative colitis resisting activity and has the potential of being developed into ulcerative colitis resisting drugs.

The invention discloses a 1, 8-disubstituted tryptanthrin derivative and application of the 1, 8-disubstituted tryptanthrin derivative to prevention and treatment of phytopathogen and anti-tumor activity, the general formula of the derivative is shown in (I), and the test result of the compound shown in the general formula on the bacterial activity of phytopathogen shows that the compound has a good antibacterial effect on Xanthomonas oryzae pv. Oryzae, Xanthomonas citri pv. Citri and the like, and can be used for preventing and treating the phytopathogen. The method can be used for developing novel agricultural bactericides. Meanwhile, results of the compound shown in the general formula on tumor cells show that the compound has good in-vitro anti-tumor activity on human chronic myelogenous leukemia cells K562, human lung cancer cell lines A549, human liver cancer cells HepG2, human prostate cancer cells PC3 and the like, and can be used for researching novel anti-tumor drugs. # imgabs0 #

The present application belongs to the technical field of pharmaceutical therapy, and particularly relates to an amide-substituted tryptophan ketone derivative, a preparation method and application thereof. The structural formula of the tryptophan ketone derivative is shown in formula (A) or formula (B). In the formula, n=1 or 2, and R is any one of dimethylamine group, diethylamine group, morpholine group, 1-methylpiperazine group, cyclopropylamine group and 4-hydroxypiperidyl group. The compound can selectively inhibit the activity of acetylcholinesterase, and has the potential to develop into a drug for treating Alzheimer's disease due to the abilities of self-aggregation and the like. 1‑42 ​

The invention belongs to the technical field of preparation of anti-inflammatory drugs, and particularly discloses a tryptanthrin derivative and a preparation method and application thereof.The structural formula of the tryptanthrin derivative is # imgabs0, R is one of R1, R2 and R3, and when R is R1, # imgabs1 # reacts with H-R1, Pd (PPh3) 2Cl, copper iodide, triethylamine and an organic solvent to prepare the tryptanthrin derivative; when R is R2, the catalyst is prepared by reacting # imgabs2 # with H-R2, Pd2 (dppf) Cl2, potassium acetate and methylbenzene; when R is R3, the PdCl (PPh3) 4 is prepared by reacting with H-R3, silver carbonate, PdCl (PPh3) 4 and acetonitrile. The tryptanthrin derivative disclosed by the invention has high biological activity and solubility and low toxicity, and has the potential of being developed into a medicine for treating ulcerative colitis.

The invention discloses a method for synthesizing novel alkaloid by enzyme catalysis of tryptamine and alpha-ketoamide substances, and the method comprises the following steps: reacting a compound shown as a formula (A) with a compound shown as a formula (B) in the presence of isoviscin synthetase to obtain alkaloid shown as a formula (C). The method is mild in condition, free of pollution and simple in process route.

Provided herein are compounds of formula (I), (II), or pharma- ceutically acceptable salts thereof.Also provided herein are pharmaceutical compositions comprising the compounds of formula (I), (II), or pharma- ceutically acceptable salts thereof, and methods of using, for example, the compounds of formula (I), (II), or pharma- ceutically acceptable salts thereof. [Formula 1] JPEG2024545787000024.jpg47137

The invention discloses an SERS (Surface Enhanced Raman Scattering) aptamer sensor based on a double-layer core-satellite magnetic gold nanostructure and a method for detecting biogenic amine in food by using the SERS aptamer sensor. The Fe3O4 (at) Au MNPs nanoparticles are combined with a nucleic acid aptamer, and a specific magnetic capture probe is obtained; the method comprises the following steps: mixing gold nanoparticle solutions with different particle sizes with 4-MBN, incubating to obtain a'biological silence zone 'SERS tag, and combining the'biological silence zone' SERS tag with pretreated sulfydryl modified c-DNA to obtain a specific SERS signal probe; and oscillating and incubating the specific SERS signal probe solution and the specific magnetic capture probe solution to obtain the SERS aptamer sensor based on the double-layer core-satellite magnetic gold nanostructure. According to the method, a'biological silence zone 'SERS label is combined with a magnetic induction technology, so that the problems of poor anti-interference performance and poor accuracy during detection of trace components in a complex matrix by SERS are solved, and high-efficiency detection of tryptamine in biogenic amine is realized.

The invention relates to tryptanthrin derivatives with thiosemicarbazone substitution of the general formulae I and II, where R1-R8 are independently H, OH, alkyl with 1 to 6 carbon atoms, C(CH3)3, allyl, propargyl, ben-zyl, phenyl, F, Cl, Br, I, CH2OH, O (alkyl), CF3, OCF3, CN, COOH, COO(alkyl), CONH2, CONH(alkyl), NO2, N(alkyl)2, NH(alkyl), NHCO(alkyl), where the alkyl has 1 to 6 carbon atoms, or R1-R2 or R2-R3 or R3-R4 or R5-R6 or R6-R7 or R7-R8 is —CH═CH—CH═CH—, i.e., a fused benzene ring, X and Z are independently H, alkyl of 1 to 6 carbon atoms, benzyl or phenyl. The compounds combine a structural motif suitable for PLpro targeting, have strong affinity and selectivity for RNA over DNA, and at the same time effectively chelate ferric and ferrous ions. Thus, these compounds have the desired properties for potential use as inhibitors of the production of SARS-COV-2 viral particles and can thus be used for the preparation drugs for the treatment of coronavirus diseases, especially COVID-19.